The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early changes in angiogenesis and hypoxia following bevacizumab therapy in primary breast cancer.
Shaveta Mehta
Research Funding - Roche
Nicholas Peter Hughes
No relevant relationships to disclose
Adrian M. Jubb
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Helen Turley
No relevant relationships to disclose
Chen Han
No relevant relationships to disclose
Sonia Patricia Li
No relevant relationships to disclose
N Jane Taylor
No relevant relationships to disclose
Anwar R. Padhani
Consultant or Advisory Role - Roche
Rosemary Frances Adams
No relevant relationships to disclose
Andreas Makris
Other Remuneration - Roche
Adrian L. Harris
Consultant or Advisory Role - Roche
Research Funding - Roche
Expert Testimony - Roche